Alcoholic liver disease

HistoIndex and Consortium Partners Awarded S$1.2M for the Development of AI-based Diagnostics Tool in the Identification of High-Risk Nonalcoholic Fatty Liver Disease Population

Retrieved on: 
Tuesday, December 15, 2020
Medical specialties, Anatomy, Hepatitis, Non-alcoholic fatty liver disease, Clinical medicine, Fatty liver disease, Liver disease, Alcoholic liver disease, Diabetes, Steatohepatitis

HistoIndex joins forces with a consortium of partners from NHS Health Boards, UK universities and technology companies for the development of a novel AI-based integrated diagnostic tool.

Key Points: 
  • HistoIndex joins forces with a consortium of partners from NHS Health Boards, UK universities and technology companies for the development of a novel AI-based integrated diagnostic tool.
  • SINGAPORE, Dec. 14, 2020 /PRNewswire/ -- HistoIndex , an AI-based digital pathology company in the stain-free assessment of NASH and other fibrosis, has joined INTErPRET-NAFLD, an international liver R&D collaboration aimed at developing an integrated precision AI diagnostics tool for High-Risk Nonalcoholic Fatty Liver Disease (NAFLD).
  • Led by the University of Edinburgh, the multi-centre collaboration was recently awarded with a S$1.2M (750,000 Euros) innovative research grant.
  • It is caused by non-alcoholic and metabolic conditions like obesity, which is rising in low- and middle-income countries, particularly in urban settings.

Galectin Therapeutics, Inc. to Present at the 4th Annual Digital NASH Summit on December 17, 2020

Retrieved on: 
Friday, December 11, 2020
Medical specialties, Clinical medicine, Medicine, Hepatitis, Non-alcoholic fatty liver disease, Fatty liver disease, Steatohepatitis, Liver disease, Liver, Cirrhosis, Galectin-3, Alcoholic liver disease

To register for the 4th Annual NASH Summit, click here: https://nash-summit.com/get-involved/register/

Key Points: 
  • To register for the 4th Annual NASH Summit, click here: https://nash-summit.com/get-involved/register/
    Belapectin (GR-MD-02) is a complex carbohydrate drug that targets galectin-3, a critical protein in the pathogenesis of fatty liver disease and fibrosis.
  • Preclinical data in animals models have shown that belapectin has robust treatment effects in reversing liverfibrosisandcirrhosis.
  • Non-alcoholic steatohepatitis (NASH) has become a common disease of the liver with the rise in obesity and other metabolic diseases.
  • Over time, patients with NASH can develop excessive fibrosis, or scarring of the liver, and ultimately liver cirrhosis.

$27.2 Billion Non-Alcoholic Steatohepatitis (NASH) Opportunity Analysis and Forecasts to 2029 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, December 9, 2020
Health, Pharmaceutical, Medical specialties, Anatomy, Clinical medicine, Histopathology, Steatohepatitis, Non-alcoholic fatty liver disease, Fatty liver disease, Hepatitis, Liver disease, Steatosis, Alcoholic liver disease, Nash

The "Non-Alcoholic Steatohepatitis (NASH) - Opportunity Analysis and Forecasts to 2029" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Non-Alcoholic Steatohepatitis (NASH) - Opportunity Analysis and Forecasts to 2029" report has been added to ResearchAndMarkets.com's offering.
  • Non-alcoholic steatohepatitis (NASH) is a common, often clinically silent liver disease characterized by the presence of steatosis (fatty liver), in addition to liver inflammation and damage.
  • Both NASH and non-alcoholic fatty liver (NAFL) are histologically categorized under the umbrella of non-alcoholic fatty liver disease (NAFLD).
  • Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of pipeline products.

Fibronostics and Fatty Liver Foundation Announce a Patient Education Partnership

Retrieved on: 
Monday, December 7, 2020
Medical specialties, Anatomy, Hepatitis, Clinical medicine, Non-alcoholic fatty liver disease, Fatty liver disease, Liver, Alcoholic liver disease, AFLD, HSD17B13, Steatohepatitis

ORLANDO, Fla.and BOISE, Idaho, Dec. 7, 2020 /PRNewswire/ --Fibronostics and the Fatty Liver Foundation are pleased to announce they have entered into a strategic collaboration, combining Fibronostics' industry leading in vitro diagnostics platform for metabolic conditions with the Fatty Liver Foundation broad outreach to patients, to help identify asymptomatic, undiagnosed liver injuries and to educate patients on the lifestyle changes needed to halt or minimize disease progression.

Key Points: 
  • ORLANDO, Fla.and BOISE, Idaho, Dec. 7, 2020 /PRNewswire/ --Fibronostics and the Fatty Liver Foundation are pleased to announce they have entered into a strategic collaboration, combining Fibronostics' industry leading in vitro diagnostics platform for metabolic conditions with the Fatty Liver Foundation broad outreach to patients, to help identify asymptomatic, undiagnosed liver injuries and to educate patients on the lifestyle changes needed to halt or minimize disease progression.
  • Non-alcoholic fatty liver disease (NAFLD) is a growing epidemiologic burden on our health care system.
  • "We are very pleased to enter into this strategic collaboration with Fibronostics," said Wayne Eskridge, President and CEO of Fatty Liver Foundation.
  • www.Fibronostics.com
    The Fatty Liver Foundation is a non-profit patient organization dedicated to improving the identification, diagnosis, treatment and support of people living with fatty liver, NAFLD or NASH through awareness, screening, education and patient outreach.

iBiopsy®: Promising Results on a Preliminary Study to Identify the Severity of the Disease in Patients With Non-Alcoholic Steatohepatitis (NASH)

Retrieved on: 
Tuesday, November 24, 2020
Oncology, Medical devices, Health, Clinical trials, Pharmaceutical, Biotechnology, Medical specialties, Liver, Clinical medicine, Non-alcoholic fatty liver disease, Steatohepatitis, Fatty liver disease, Hepatitis, Cirrhosis, Liver disease, Alcoholic liver disease, Liver cancer, HSD17B13

According to the World Health Organization (WHO), Non-Alcoholic Fatty Liver Disease (NAFLD) is a pandemic affecting 25% of the global population1.

Key Points: 
  • According to the World Health Organization (WHO), Non-Alcoholic Fatty Liver Disease (NAFLD) is a pandemic affecting 25% of the global population1.
  • For 20% of patients, NAFLD leads to a more severe disease, Non-Alcoholic Steatohepatitis (NASH).
  • Within the high-risk population of NASH patients, disease evolution can lead to cirrhosis and liver cancer.
  • In this clinical context, the objective of Medians preliminary retrospective study was to quantify the ability of iBiopsys learning algorithms to discriminate between early and advanced fibrosis grade in NASH patients.

ChronWell, ModifyHealth and Echosens North America Partner to Create LIVErHEALTHY Program for Managing Liver Disease

Retrieved on: 
Thursday, November 12, 2020
Medical specialties, Anatomy, Hepatitis, Clinical medicine, Non-alcoholic fatty liver disease, Steatohepatitis, Fatty liver disease, Liver disease, Alcoholic liver disease, Chronic liver disease, Liver, HSD17B13

This collaboration will create LIVErHEALTHY, a newly integrated program that provides better outcomes and best-in-class service for Medicare patients managing chronic liver diseases, including non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).

Key Points: 
  • This collaboration will create LIVErHEALTHY, a newly integrated program that provides better outcomes and best-in-class service for Medicare patients managing chronic liver diseases, including non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).
  • Providing a holistic, tailored and technology-enabled approach to managing chronic liver diseases, LIVErHEALTHY links ChronWell's Chronic Care Management (CCM) Program with ModifyHealth's intuitive food and diet regime, and Echosen's frequent non-invasive liver testing.
  • "This strategic partnership is a powerful combination that reflects our collective commitment to ending the epidemic of fatty liver disease and halting the progression of NAFLD/NASH," said Jon Gingrich, CEO of Echosens North America.
  • "FibroScan complements the LIVErHEALTHY program and its treatment strategies, proving to be an important tool for improving individual patient outcomes.

Echosens Introduces FibroScan 630 Expert: Adds New Spleen Stiffness Measurement (SSM by VCTE™) for Risk Stratification of Patients with Advanced Chronic Liver Disease

Retrieved on: 
Monday, November 9, 2020
Technology, Medical devices, Infectious diseases, Hospitals, Biotechnology, Radiology, Managed care, Health, Data management, Medical specialties, Clinical medicine, Hepatitis, Elastography, Medical imaging, Cirrhosis, Non-alcoholic fatty liver disease, Steatohepatitis, Esophageal varices, Liver, Varices, Alcoholic liver disease

Echosens , a high-technology company offering the FibroScan family of products, announces the launch of FibroScan 630 Expert in the United States, a comprehensive non-invasive solution for advanced liver disease management.

Key Points: 
  • Echosens , a high-technology company offering the FibroScan family of products, announces the launch of FibroScan 630 Expert in the United States, a comprehensive non-invasive solution for advanced liver disease management.
  • This innovative tool is designed to expand clinical capabilities in liver health assessment with the addition of spleen stiffness measurement.
  • Given the significant increase in potential cases of liver cirrhosis due to non-alcoholic steatohepatitis (NASH) and alcoholic liver disease, there is a critical need for a non-invasive evaluation tool like FibroScan 630 Expert.
  • In cirrhotic patients, spleen stiffness may correlate better with Hepatic Venous Pressure Gradient (HVPG) and presence of high-risk esophageal varices than liver stiffness.

Can-Fite to Present its NASH Program in Fireside Chat at the H.C. Wainwright 6th Annual Israel Conference on November 12, 2020

Retrieved on: 
Monday, November 9, 2020
Oncology, Health, Infectious diseases, Clinical trials, Pharmaceutical, Biotechnology, Medical specialties, Hepatitis, Clinical medicine, Anatomy, Non-alcoholic fatty liver disease, Steatohepatitis, Fatty liver disease, Liver disease, Nash, Alcoholic liver disease

Dr. Fishmans chat will focus on Can-Fites Namodenoson in the treatment of non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD).

Key Points: 
  • Dr. Fishmans chat will focus on Can-Fites Namodenoson in the treatment of non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD).
  • The NASH market is projected to reach at least $35 billion by 2025.
  • There are currently no other treatment options approved for this growing unmet need.
  • Can-Fite does not undertake any obligation to publicly update these forward-looking statements, whether as a result of new information, future events or otherwise.

Galmed Pharmaceuticals to Report Third Quarter 2020 Financial Results and Provide Business Update on Thursday November 12

Retrieved on: 
Thursday, November 5, 2020
Medical specialties, Anatomy, Branches of biology, Histopathology, Hepatitis, Fatty liver disease, Non-alcoholic fatty liver disease, Steatosis, Liver disease, Bile acids, Alcoholic liver disease, Cirrhosis

Aramchol's ability to modulate hepatic lipid metabolism was discovered and validated in animal models, demonstrating downregulation of the three key pathologies of NASH: steatosis, inflammation and fibrosis.

Key Points: 
  • Aramchol's ability to modulate hepatic lipid metabolism was discovered and validated in animal models, demonstrating downregulation of the three key pathologies of NASH: steatosis, inflammation and fibrosis.
  • The effect of Aramchol on fibrosis is mediated by downregulation of steatosis and directly on human collagen producing cells.
  • NASH is the progressive form of non-alcoholic fatty liver disease that can lead to cardiovascular disease, cirrhosis and liver-related mortality.
  • Galmed Pharmaceuticals Ltd. is a clinical stage drug development biopharmaceutical company for liver, metabolic and inflammatory diseases.

New PBC and NASH Data to be Presented at AASLD’s The Liver Meeting Digital Experience™

Retrieved on: 
Thursday, October 29, 2020
Medical specialties, Clinical medicine, Hepatology, Organ transplantation, Liver transplantation, Liver, Hepatitis, Biopsy, Non-alcoholic fatty liver disease, Alcoholic liver disease

Advanced fibrosis is associated with a substantially higher risk of liver-related morbidity and mortality in patients with NASH.

Key Points: 
  • Advanced fibrosis is associated with a substantially higher risk of liver-related morbidity and mortality in patients with NASH.
  • In the United States, NASH is currently the second leading cause for liver transplantation overall, and in females, the leading cause.
  • NASH is anticipated to become the leading indication for liver transplantation in Europe within the next decade.
  • A pre-specified 18-month analysis was conducted to assess the effect of OCA on liver histology comparing month 18 biopsies with baseline.